These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23127271)

  • 1. Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): a 6.5-year detailed follow-up.
    Jurecka A; Marucha J; Jurkiewicz E; Różdżyńska-Świątkowska A; Tylki-Szymańska A
    Pediatr Neurol; 2012 Dec; 47(6):461-5. PubMed ID: 23127271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up.
    Gabrielli O; Clarke LA; Bruni S; Coppa GV
    Pediatrics; 2010 Jan; 125(1):e183-7. PubMed ID: 20026495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Remmington T
    Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment.
    Gabrielli O; Clarke LA; Ficcadenti A; Santoro L; Zampini L; Volpi N; Coppa GV
    BMC Med Genet; 2016 Mar; 17():19. PubMed ID: 26965916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).
    Wraith JE; Beck M; Lane R; van der Ploeg A; Shapiro E; Xue Y; Kakkis ED; Guffon N
    Pediatrics; 2007 Jul; 120(1):e37-46. PubMed ID: 17606547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I.
    Laraway S; Mercer J; Jameson E; Ashworth J; Hensman P; Jones SA
    J Pediatr; 2016 Nov; 178():219-226.e1. PubMed ID: 27788836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
    Sifuentes M; Doroshow R; Hoft R; Mason G; Walot I; Diament M; Okazaki S; Huff K; Cox GF; Swiedler SJ; Kakkis ED
    Mol Genet Metab; 2007 Feb; 90(2):171-80. PubMed ID: 17011223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome.
    Thomas JA; Jacobs S; Kierstein J; Van Hove J
    J Inherit Metab Dis; 2006 Dec; 29(6):762. PubMed ID: 17089217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme-replacement therapy in mucopolysaccharidosis I.
    Kakkis ED; Muenzer J; Tiller GE; Waber L; Belmont J; Passage M; Izykowski B; Phillips J; Doroshow R; Walot I; Hoft R; Neufeld EF
    N Engl J Med; 2001 Jan; 344(3):182-8. PubMed ID: 11172140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Wraith JE
    Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
    Jameson E; Jones S; Wraith JE
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scheie syndrome: enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression.
    Illsinger S; Lücke T; Hartmann H; Mengel E; Müller-Forell W; Donnerstag F; Das AM
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S321-5. PubMed ID: 19894140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy with laronidase (Aldurazyme
    Jameson E; Jones S; Remmington T
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD009354. PubMed ID: 31211405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
    Clarke LA; Wraith JE; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Sidman M; Kakkis ED; Cox GF
    Pediatrics; 2009 Jan; 123(1):229-40. PubMed ID: 19117887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Laronidase for treating post-surgical respiratory failure in a patient with type I mucopolysaccharidosis].
    Vélez-Díaz-Pallarés M; Sánchez Cuervo M; Martínez-Pardo Casanova M; Bermejo Vicedo T
    Farm Hosp; 2012; 36(1):55-6. PubMed ID: 21641259
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report].
    Dupont C; El Hachem C; Harchaoui S; Ribault V; Amiour M; Guillot M; Maire I; Froissart R; Guffon-Fouilhoux N
    Arch Pediatr; 2008 Jan; 15(1):45-9. PubMed ID: 18162380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The development of cognitive functions in children with Hurler phenotype mucopolysaccharidosis type I on enzyme replacement therapy with laronidase].
    Biernacka M; Jakubowska-Winecka A; Tylki-Szymańska A
    Pediatr Endocrinol Diabetes Metab; 2010; 16(4):249-54. PubMed ID: 21447265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome.
    Bijarnia S; Shaw P; Vimpani A; Smith R; Pacey V; O'Grady H; Christodoulou J; Sillence D
    J Paediatr Child Health; 2009; 45(7-8):469-72. PubMed ID: 19712183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up.
    Tylki-Szymanska A; Jurecka A; Zuber Z; Rozdzynska A; Marucha J; Czartoryska B
    Acta Paediatr; 2012 Jan; 101(1):e42-7. PubMed ID: 21672014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.
    Tylki-Szymanska A; Marucha J; Jurecka A; Syczewska M; Czartoryska B
    J Inherit Metab Dis; 2010 Apr; 33(2):151-7. PubMed ID: 20217237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.